AI Science Tracker

Rutgers University–New Jersey Medical School

1 discovery from 2022

Discoveries

Random forest prioritizes dual-stage antimalarial compounds

A random forest trained on parasite activity data screened commercial compounds; 100 predicted actives and 20 predicted inactives were tested. The primary manuscript reports 18 dose-response-validated compounds with liver- and blood-stage activity among 26 liver-stage hits. The selected sets are not population samples, and assays used P. berghei liver-stage and P. falciparum blood-stage parasites.

Technology: Random-forest classifier

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Primary indexed Methods/Results report 18 dual-stage validated compounds and screening denominators.
  • Still unknown: Chemical prior art, complete supplemental details and clinical translation remain open; do not present 18/26 as general hit rate.
  • AI role: Classifier prioritizes compounds from >1.5 million virtual candidates; human structural-diversity selection and assays follow.

Evidence sources: https://doi.org/10.1021/acsinfecdis.2c00189

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 16 Nov 2026. Review scope: PMC-indexed primary manuscript text; publisher primary metadata/index. Material checked for the specific claims stated in the record..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.